$海正药业(SH600267)$ $吉利德科学(GILD)$ $博腾股份(SZ300363)$ 因为昨天看到伊维霉素在美国也有人搞临床，所以研究了下。然后发现一个报告挺有意思。这个不吹海正，仅写给神药党看看。

------------------------------------------------------------------------------------------------------

In an observational registry-based study from 169 hospitals across Asia (AS), Europe (EU), Africa (AF), North (NA) and South America (SA), we evaluated critically ill hospitalized patients diagnosed with COVID-19 with lung injury requiring mechanical ventilation, between January 1st 2020 and March 1st 2020. In this series of 1,970 patients, 1,609 survived hospitalization to discharge and 361 died (18.3%). 

简而言之，观察了全球169家医院1970个病例（全部使用呼吸机，视为危重），361死亡，死亡率18.3%。

神药党：我们remdesivir主要救重症，能够将死亡率降低到18.3%。====》这脸打得啪啪响啊。难道上面1970个全部都用了remdesivir？

———————————————————————————————————————

We recorded 52 patients (AS-7, EU-21, AF-3, NA-14, SA-7) who received Ivermectin (150 mcg/Kg) once after mechanical ventilation was instituted. The indications for use of the drug were related to clinician preference and based on prior data on the broad antimicrobial and specifically antiviral effects of this agent. Compared to 1,918 conventionally treated patients we observed a survival benefit for ivermectin (mortality rate 18.6% vs 7.7%）

简而言之：我们记录了52例使用了伊维霉素的病例，跟全部病例的死亡率对比率为（18.6% VS 7.7%）。。。。这个尴尬了啊，伊维霉素的重症病死率比神药还低？

———————————————————————————————————————

要吵架的麻烦拿数据来反驳。不然直接拉黑。谢谢。